BioCentury
ARTICLE | Clinical News

LL-37: Phase I/II started

September 17, 2012 7:00 AM UTC

Pergamum began a double-blind, placebo-controlled, Swedish Phase I/II trial to evaluate 3 doses of LL-37 for 1 month in 32 patients. ...